



February 12, 2025  
JCR Pharmaceuticals Co., Ltd.

Translation

### Notice of Partial Correction to “FY2024 Third Quarter Consolidated Financial Results Conference Call Material”

The text reported in “Additional Remarks” of “FY2024 Third Quarter Consolidated Financial Results Conference Call Material” which was announced on January 31, 2025 should be corrected as specified in the following. The text after the correction are underlined>.

#### Description

“FY2024 Third Quarter Consolidated Financial Results Conference Call Material” announced on January 31, 2025

Page 3

(Before correction)

#### Overview: Consolidated Financial Results

Reach Beyond, Together 

Consolidated	FY2023		FY2024		(Unit : million yen)
	Q3 YTD	Q3 YTD	Year-on-year		
			Difference	Ratio	
Net Sales	33,718	<u>25,880</u>	(7,837)	(23.2%)	<b>Additional Remarks</b> <ul style="list-style-type: none"> <li>• Cost to sales ratio excluding contractual payment remained favorable</li> <li>• Depreciation from the new formulation facility at Kobe Science Park Center is included in General and Administrative Expenses and is expected to be offset against the “Special suspense account for tax purpose reduction entry” (by advanced depreciation) account by fiscal year-end</li> <li>• The increase in R&amp;D Expenses was mainly due to the establishment of overseas development structures and the advancement of clinical trials</li> <li>• Extraordinary Income includes from Gain on reversal of share acquisition rights and Gain on cancellation of contract</li> </ul>
Cost of Sales	8,423	<u>7,007</u>	(1,415)	(16.8%)	
Gross Profit	25,295	<u>18,873</u>	(6,422)	(25.4%)	
Selling, General and Administrative Expenses	17,486	<u>19,627</u>	+2,141	+12.2%	
SG&A Expenses	9,127	<u>9,702</u>	+575	+6.3%	
R&D Expenses	8,359	<u>9,925</u>	+1,566	+18.7%	
Operating Profit	7,809	<u>(754)</u>	(8,563)	-	
Non-operating Income	575	<u>200</u>	(374)	(65.1%)	
Non-operating Expenses	995	<u>827</u>	(168)	(16.9%)	
Ordinary Profit	7,388	<u>(1,380)</u>	(8,769)	-	
Extraordinary Income	0	<u>1,065</u>	+1,064	-	
Extraordinary Losses	18	<u>2</u>	(15)	(88.5%)	
Profit before Income Taxes	7,371	<u>(317)</u>	(7,688)	-	
Income Taxes	2,210	<u>258</u>	(1,951)	(88.3%)	
Profit Attributable to Owners of Parent	5,160	<u>(576)</u>	(5,737)	-	
Reference: R&D Expenses before Deducting Contribution Amount by Collaborative R&D Destinations	9,508	<u>11,121</u>	+1,613	+17.0%	

	FY2023 Q3 YTD	FY2024 Q3 YTD	Difference
Net Sales			
Cost of Sales Ratio	25.0%	<u>27.1%</u>	+2.1%
Cost of Sales Ratio *Excluding income from contractual payment	31.7%	<u>27.6%</u>	(4.0%)
R&D Expenses Ratio	24.8%	<u>38.3%</u>	+13.6%
Operating Profit Ratio	23.2%	<u>(2.9%)</u>	(26.1%)

YTD: year to date 3

(After correction)

## Overview: Consolidated Financial Results

Reach Beyond, Together 

Consolidated	(Unit : million yen)			
	FY2023	FY2024		
	Q3 YTD	Q3 YTD	Year-on-year	
			Difference	Ratio
Net Sales	33,718	<u>25,880</u>	(7,837)	(23.2%)
Cost of Sales	8,423	<u>7,007</u>	(1,415)	(16.8%)
Gross Profit	25,295	<u>18,873</u>	(6,422)	(25.4%)
Selling, General and Administrative Expenses	17,486	<u>19,627</u>	+2,141	+12.2%
SG&A Expenses	9,127	<u>9,702</u>	+575	+6.3%
R&D Expenses	8,359	<u>9,925</u>	+1,566	+18.7%
Operating Profit	7,809	<u>(754)</u>	(8,563)	-
Non-operating Income	575	<u>200</u>	(374)	(65.1%)
Non-operating Expenses	995	<u>827</u>	(168)	(16.9%)
Ordinary Profit	7,388	<u>(1,380)</u>	(8,769)	-
Extraordinary Income	0	<u>1,065</u>	+1,064	-
Extraordinary Losses	18	<u>2</u>	(15)	(88.5%)
Profit before Income Taxes	7,371	<u>(317)</u>	(7,688)	-
Income Taxes	2,210	<u>258</u>	(1,951)	(88.3%)
Profit Attributable to Owners of Parent	5,160	<u>(576)</u>	(5,737)	-
Reference: R&D Expenses before Deducting Contribution Amount by Collaborative R&D Destinations	9,508	<u>11,121</u>	+1,613	+17.0%

### Additional Remarks

- Cost to sales ratio excluding contractual payment remained favorable
- Depreciation from the API Plant at Kobe Science Park Center is included in General and Administrative Expenses and is expected to be offset against the "Special suspense account for tax purpose reduction entry" (by advanced depreciation) account by fiscal year-end
- The increase in R&D Expenses was mainly due to the establishment of overseas development structures and the advancement of clinical trials
- Extraordinary Income includes from Gain on reversal of share acquisition rights and Gain on cancellation of contract

Net Sales	FY2023 Q3 YTD	FY2024 Q3 YTD	Difference
Cost of Sales Ratio	25.0%	<u>27.1%</u>	+2.1%
Cost of Sales Ratio *Excluding income from contractual payment	31.7%	<u>27.6%</u>	(4.0%)
R&D Expenses Ratio	24.8%	<u>38.3%</u>	+13.6%
Operating Profit Ratio	23.2%	<u>(2.9%)</u>	(26.1%)

On February 12 2025, Additional Remarks was corrected. Correction is indicated by underlining. YTD: year to date 3

### About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and belief – benefit all our stakeholders, including patients, partners, and employees. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

### Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jp.jcrpharm.com](mailto:ir-info@jp.jcrpharm.com)

###